Biotheryx, Inc

Biotheryx is a clinical-stage biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders, including bifunctional degraders and molecular glues. Our focus is on deploying the differentiated potential of degraders towards validated targets in cancer and inflammatory disease. Members of our founding and scientific teams previously developed the IMiDs, the first U.S. Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and we have applied our expertise in Cereblon binding to build our proprietary PRODEGY platform. Biotheryxs clinical program, BTX-9341, a bifunctional degrader of CDK4 and CDK6, began a...

Biotech,targeted protein degredation,cancer,small molecules ,and inflammatory disorders

Biotheryx, inc operates in the Biotechnology research industry.

Biotheryx, inc's revenue is 11m - 100m

Biotheryx, inc has 11 - 50 employees.